STOCK TITAN

Indaptus Therapeutics to Present at 34th Annual ROTH Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Indaptus Therapeutics (Nasdaq: INDP) announced that CEO Jeffrey Meckler will present at the 34th Annual ROTH Conference on March 14-15, 2022. An audio webcast of this presentation is available here and on the company's website, where it will be archived for 90 days. Indaptus focuses on immunotherapy, employing a multi-targeted approach for anti-tumor and anti-viral responses.

Positive
  • None.
Negative
  • None.

NEW YORK, March 07, 2022 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) ("Indaptus" or the "Company”), today announced that Jeffrey Meckler, Chief Executive Officer, will participate in an on demand pre-recorded presentation at the 34th Annual ROTH Conference which is taking place March 14 – 15, 2022.

An audio webcast of the presentation is available here and on the Investor Relations section of Indaptus' website, where it will be archived for approximately 90 days.

About Indaptus Therapeutics

Indaptus Therapeutics has evolved from more than a century of immunotherapy advances. The Company's approach is based on the hypothesis that efficient activation of both innate and adaptive immune cells and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system activating signals that can be administered safely intravenously. Indaptus' patented technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria, with reduced i.v. toxicity, but largely uncompromised ability to prime or activate many of the cellular components of innate and adaptive immunity. This approach has led to broad anti-tumor and anti-viral activity, including safe, durable anti-tumor response synergy with each of five different classes of existing agents, including checkpoint therapy, targeted antibody therapy and low-dose chemotherapy in preclinical models. Tumor eradication by Indaptus technology has demonstrated activation of both innate and adaptive immunological memory and, importantly, does not require provision of or targeting a tumor antigen in pre-clinical models. Indaptus has carried out successful GMP manufacturing of its lead clinical oncology candidate, Decoy20, and have completed other IND enabling studies.

Forward-Looking Statements

This press release contains forward-looking statements with the meaning of the Private Securities Litigation Reform Act. These include statements regarding management's expectations, beliefs and intentions regarding, among other things, our product development efforts, business, financial condition, results of operations, strategies, plans and prospects. Forward-looking statements can be identified by the use of forward-looking words such as "believe", "expect", "intend", "plan", "may", "should", "could", "might", "seek", "target", "will", "project", "forecast", "continue" or "anticipate" or their negatives or variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical matters. Forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause our actual results to differ materially from any future results expressed or implied by the forward-looking statements. Many factors could cause actual activities or results to differ materially from the activities and results anticipated in forward-looking statements, including, but not limited to, the following: Indaptus' plans to develop and potentially commercialize its technology, the timing and cost of Indaptus' planned investigational new drug application and any clinical trials, the completion and receiving favorable results in any clinical trials, Indaptus' ability to obtain and maintain regulatory approval of any product candidate, Indaptus' ability to protect and maintain its intellectual property and licensing arrangements, Indaptus' ability to develop, manufacture and commercialize its product candidates, the risk of product liability claims, the availability of reimbursement, the influence of extensive and costly government regulation, and Indaptus' estimates regarding future revenue, expenses capital requirements and the need for additional financing following the merger. These risks, as well as other risks are discussed in the proxy statement/prospectus that was included in the registration statement on Form S-4 filed with the SEC in connection with the merger. All forward-looking statements speak only as of the date of this press release and are expressly qualified in their entirety by the cautionary statements included in this press release. We undertake no obligation to update or revise forward-looking statements to reflect events or circumstances that arise after the date made or to reflect the occurrence of unanticipated events, except as required by applicable law.

Investor Contact:
Will O'Connor  
Stern IR  
+1 212-362-1200  
will@sternir.com 


FAQ

What is the date of the 34th Annual ROTH Conference for Indaptus (INDP)?

The 34th Annual ROTH Conference will take place on March 14-15, 2022.

Who is presenting on behalf of Indaptus at the ROTH Conference?

Jeffrey Meckler, the CEO of Indaptus, will present at the conference.

Where can I find the audio webcast of Indaptus' presentation?

The audio webcast can be found here and on Indaptus' Investor Relations website.

What technology does Indaptus Therapeutics focus on?

Indaptus focuses on a multi-targeted immunotherapy approach for activating both innate and adaptive immune responses.

How long will the audio presentation be available for Indaptus (INDP)?

The audio presentation will be archived for approximately 90 days.

Indaptus Therapeutics, Inc.

NASDAQ:INDP

INDP Rankings

INDP Latest News

INDP Stock Data

10.92M
9.25M
26.67%
6%
1.36%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
NEW YORK